Last reviewed · How we verify

Combination of dexamethasone + dexmedetomidine

Al-Azhar University · Phase 3 active Small molecule

Combination of dexamethasone + dexmedetomidine is a Corticosteroid + alpha-2 adrenergic agonist combination Small molecule drug developed by Al-Azhar University. It is currently in Phase 3 development for Perioperative sedation and analgesia (Phase 3 investigational), Reduction of postoperative inflammation and delirium (Phase 3 investigational).

This combination uses dexamethasone (a corticosteroid) to reduce inflammation and dexmedetomidine (an alpha-2 agonist) to provide sedation and analgesia, working synergistically for perioperative or critical care management.

This combination uses dexamethasone (a corticosteroid) to reduce inflammation and dexmedetomidine (an alpha-2 agonist) to provide sedation and analgesia, working synergistically for perioperative or critical care management. Used for Perioperative sedation and analgesia (Phase 3 investigational), Reduction of postoperative inflammation and delirium (Phase 3 investigational).

At a glance

Generic nameCombination of dexamethasone + dexmedetomidine
SponsorAl-Azhar University
Drug classCorticosteroid + alpha-2 adrenergic agonist combination
TargetGlucocorticoid receptor (dexamethasone); alpha-2A adrenergic receptor (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia, Critical Care, Perioperative Medicine
PhasePhase 3

Mechanism of action

Dexamethasone suppresses inflammatory responses and immune activation through glucocorticoid receptor binding, reducing cytokine production and edema. Dexmedetomidine acts as a selective alpha-2 adrenergic agonist in the central nervous system, providing sedation, analgesia, and anxiolysis while maintaining airway reflexes. Together, they may reduce perioperative stress response and improve patient outcomes in surgical or intensive care settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combination of dexamethasone + dexmedetomidine

What is Combination of dexamethasone + dexmedetomidine?

Combination of dexamethasone + dexmedetomidine is a Corticosteroid + alpha-2 adrenergic agonist combination drug developed by Al-Azhar University, indicated for Perioperative sedation and analgesia (Phase 3 investigational), Reduction of postoperative inflammation and delirium (Phase 3 investigational).

How does Combination of dexamethasone + dexmedetomidine work?

This combination uses dexamethasone (a corticosteroid) to reduce inflammation and dexmedetomidine (an alpha-2 agonist) to provide sedation and analgesia, working synergistically for perioperative or critical care management.

What is Combination of dexamethasone + dexmedetomidine used for?

Combination of dexamethasone + dexmedetomidine is indicated for Perioperative sedation and analgesia (Phase 3 investigational), Reduction of postoperative inflammation and delirium (Phase 3 investigational).

Who makes Combination of dexamethasone + dexmedetomidine?

Combination of dexamethasone + dexmedetomidine is developed by Al-Azhar University (see full Al-Azhar University pipeline at /company/al-azhar-university).

What drug class is Combination of dexamethasone + dexmedetomidine in?

Combination of dexamethasone + dexmedetomidine belongs to the Corticosteroid + alpha-2 adrenergic agonist combination class. See all Corticosteroid + alpha-2 adrenergic agonist combination drugs at /class/corticosteroid-alpha-2-adrenergic-agonist-combination.

What development phase is Combination of dexamethasone + dexmedetomidine in?

Combination of dexamethasone + dexmedetomidine is in Phase 3.

What are the side effects of Combination of dexamethasone + dexmedetomidine?

Common side effects of Combination of dexamethasone + dexmedetomidine include Hypotension, Bradycardia, Hyperglycemia, Sedation/drowsiness, Dry mouth.

What does Combination of dexamethasone + dexmedetomidine target?

Combination of dexamethasone + dexmedetomidine targets Glucocorticoid receptor (dexamethasone); alpha-2A adrenergic receptor (dexmedetomidine) and is a Corticosteroid + alpha-2 adrenergic agonist combination.

Related